anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
FIELD: cellular immunotherapy.SUBSTANCE: invention relates to a composition for expanding lymphocyte, a method of producing a population of clinically significant lymphocytes, to a method of treating or preventing diseases in a mammal (versions), to using a kit in immunotherapy, to a clinically significant lymphocyte (versions), to a population of clinically significant lymphocytes (versions). Composition for lymphocyte expansion contains interleukin-2 (IL-2), interleukin-15 (IL-15) and interleukin-21 (IL-21) in certain concentrations, wherein the composition is in a liquid form. Method for producing a population of clinically significant lymphocytes involves a number of steps: obtaining a tissue sample or body fluid sample, body in vitro culture of the sample for expansion and/or stimulation of lymphocytes in the sample, wherein the culturing involves using IL-2, IL-15 and IL-21 taken in certain concentrations, determining the presence of a clinically significant lymphocyte in the cultured sample. Method of treating or preventing a malignant disease in a mammal, involving certain stages. Method of treating or preventing an infectious disease in a mammal, involving certain stages. Method of treating or preventing an autoimmune disease in a mammal, involving certain stages. Use of kit in immunotherapy, where kit contains IL-2, IL-15 and IL-21, taken in certain concentrations, in liquid composition, a component which stimulates TCR-costimulatory molecules, feeder cells and a peptide comprising a sequence of at least one clinically significant antigen. Clinically significant lymphocyte obtained by said method (versions). Population of clinically significant lymphocytes obtained by the above method (versions).EFFECT: described above enables to ensure successful expansion of lymphocytes against a variety of different tumors due to the developed agents and methods for obtaining a product of expanded lymphocytes with improved composition of T-cell phenotypes for effective ACT applicable for other types of tumors.38 cl, 18 tbl, 42 ex, 33 dwg
Genetic testing is recommended in the diagnosis of short QT syndrome. This rare inherited lethal entity is characterized by structural normal hearts with short QT intervals in the electrocardiogram. Few families diagnosed with this arrhythmogenic disease have been reported worldwide so far, impeding a comprehensive understanding of this syndrome. Unraveling the origin of the disease helps to the early identification of genetic carriers at risk. However, only rare variants with a definite deleterious role should be actionable in clinical practice. Our aim was to perform a comprehensive update and reinterpretation, according to the American College of Medical Genetics and Genomics recommendations of all rare variants currently associated with short QT syndrome. We identified 34 rare variants. Reanalysis showed that only nine variants played a deleterious role associated with a definite short QT syndrome phenotype. These variants were located in the four main genes: KCNQ1, KCNH2, KCNJ2 or SLC4A3. Additional rare variants located in other genes were associated with other conditions with phenotypic shortened QT intervals, but not definite diagnosis of short QT syndrome. Periodically updating of rare variants, especially those previously classified as unknown, helps to clarify the role of rare variants and translate genetic data into clinical practice.
<P>PROBLEM TO BE SOLVED: To provide a power generating device for a diesel vehicle for utilizing headwind as wind energy as much as possible while reducing increase of fuel consumption of the diesel vehicle caused by the headwind as much as possible, to provide an emergency medical support electronic chart system utilizing the power generating device as a power source, and to provide a control system.  <P>SOLUTION: A housing 60 of a wind mill unit WU is arranged for a windscreen wall part 21a extending upward above an upper wall 12 of a cabin 10 of a truck at its rear part side in a lateral direction of the upper wall. A wind mill 70 has a plurality of Darius type blades 76 which are supported by a rotary shaft 71 via a plurality of pairs of right-and-left side stays 77, 78. The rotary shaft 71 is rotatably supported by right and left walls 62, 63 of a housing 60 via right and left side bearings 72, 73. A generator 80 is supported coaxially with the rotary shaft by the right wall 63 and generates electricity in accordance with rotation of the wind mill 70 accompanying travel of the truck against the headwind.  <P>COPYRIGHT: (C)2010,JPO&INPIT
This study investigated the effects of nanoplastics (NPs) of varying particle sizes (75, 500, and 1000 nm) and concentrations (2.5 and 10 mg/L) on the gut health of Chiromantes dehaani. The experimental groups included a control (Cg0), and varying combinations of particle size and concentration. Our results showed that 75 nm NPs were more likely to enhance pathogenic bacterial growth than other sized NPs. Compared with CK, Low NPs concentrations (2.5 mg/L) raised total cholesterol (T-CHO) levels in the gut, while high concentrations significantly decreased both triglyceride (TG) and T-CHO levels (p < 0.05). The enzymatic activities of intestinal lipase and amylase were inhibited by NPs exposure, with greater inhibition at higher NPs concentrations. The 500 nm NPs exhibited a notably higher inhibitory effect than the 75 and 1000 nm NPs (P < 0.05). In terms of apoptosis, NPs exposure led to reduced mRNA expression of Bcl2 and increased expression of Caspase-3, Caspase-8, and Caspase-9, indicating an induction of apoptosis. This effect was more pronounced at higher NPs concentrations, with 75 nm NPs more likely to induce apoptosis in intestinal cells than 500 nm and 1000 nm NPs. Moreover, NPs triggered intestinal inflammatory responses, evidenced by the increased mRNA expression of TNF-β, TNF-α, IL1β, IL6, and IL8, and the decreased expression of IL10. High NPs concentrations were more likely to induce intestinal inflammation, with 500 nm NPs imparting the strongest effect. In summary, the study demonstrated that NPs, and particularly those at higher concentrations, disrupted the gut environment of C. dehaani by altering the microflora, reducing microbial diversity, inhibiting digestion and metabolism, inducing apoptosis, and triggering inflammation. Among the sizes of NPs tested, 500 nm NPs had the most significant adverse impact on digestion, metabolism, and inflammation, while 75 nm NPs most strongly induced apoptosis in C. dehaani's intestinal cells.
FIELD: medicine, pharmacy. SUBSTANCE: invention relates to particles of sustained release involving androgenic steroid dispersed in biologically degradable polymeric binding substance at their mass ratio from 1:4 to 7:3, respectively. Medroxyprogesterone acetate or megestrol acetate are used as an androgenic steroid. Biological decomposition of polymeric binding substance promotes to release of indicated androgenic steroid at the rate and duration that provide its concentration in blood serum from 1.0 to 50.0 nM/l for period from 48 h to 28 days after administration. Invention relates to also a method of activation of androgenic receptors, a method of inhibition of breast cancer cells and a method of contraception providing administration of therapeutically effective doses of their part of prolonged release of drug. New injection delivery systems of the sustained release of medroxyprogesterone acetate and megestrol acetate ensure to maintain low concentration of these steroids in blood for the long time, for example, one month and more and have minimal amounts of toxic residual organic solvent content and show minimal masculinizing effect. EFFECT: decreased cost of the method. 9 cl, 15 dwg, 2 tbl, 13 ex
Adults, both genders, no age limit. They will be provided with topical medication, to be used 5 times a day. They will follow standard prophylactic measures and use PPE as suggested by OMS.
BACKGROUND: The aim of this registry study was to evaluate the progress of osteoarthrosis (OA) symptoms after the intake of a new standardized supplement combination (Pycnogenol® + Centellicum®, both Horphag Research) in a group of subjects with OA.
METHODS: Supplemented subjects took daily 150 mg Pycnogenol® + 450 mg Centellicum® for 6 months. Another comparable group of subjects using only standard management (SM) was included as a reference.
RESULTS: Forty-five subjects with a mean age of 42 years completed the study, 25 in the supplemented group and 20 in the SM group. There were no safety problems or tolerability issues with the supplements. The two groups, SM and SM + Pycnogenol® + Centellicum® were comparable for age and clinical characteristics at inclusion. The two main ultrasound characteristics of cartilage, its thickness and surface-irregularity were more improved with the supplements. Pain scores, C reactive protein, the level of fitness and the use of extra pain killers (as rescue medication) were all significantly improved at 6 months with the supplement combination compared to SM (P<0.05). Plasma free radicals, pain-free walking distance on treadmill and erythrocyte sedimentation rate (ESR) were significantly improved with the supplements compared to SM.
CONCLUSIONS: The morphological improvement - visible with ultrasound - correlates with a decrease in clinical symptoms and with a more efficient ambulation without pain. SM along with the Pycnogenol® Centellicum® combination are useful to avoid drug treatments that may expose patients to some side effects over time.
Since all participants have sub-optimal daytime BP control (grade I HT), they will be given an information sheet about lifestyle treatment for HT and be advised to adhere to these lifestyle changes at recruitment by the research assistant or research nurse (to participants in both arms). For grade I HT, it is the standard clinical practice to advise non-pharmacological treatment for a few months before increasing the doses of medications. (2) There is no additional intervention provided to the standard care group. The case doctors and the patients in the standard care arm will be informed not to amend drug treatment before the ABPM at the 8-week end-point (primary end-point in future definitive RCT). In Hong Kong, patients have unlimited access to publicly-funded primary care clinics and emergency departments for any health problem. This is not limited to participants in the trial.
This natural history study seeks to determine some of the mycobacterial and host factors involved in the failure of antituberculous chemotherapy, disease recurrence, and the development of multidrug resistance by M. tuberculosis. Despite optimal treatment with directly-observed short-course therapy (DOTS), about 5-10% of compliant patients with "cured" tuberculosis relapse, usually within a year after completion of therapy. In Korea, where DOTS is not practiced, the relapse rate has been reported to be 15 to 20 %. In individual patients, failure to eradicate disease contributes directly to the development of drug-resistance and to low overall cure rates. While factors such as patient drug compliance and HIV status have been extensively studied in relation to rates of relapse; host genetic factors and the specific relevance of the infecting mycobacterial strain have not yet been investigated in detail. Identification of patient characteristics and specific strains of M. tuberculosis that are associated with relapse and the evolution of drug resistance would greatly facilitate the development of treatment protocols that might avoid these complications.

Our study population will consist of subjects with pulmonary tuberculosis receiving treatment at our study sites. Healthy volunteers will be selected as the genotypic control population. All subjects with tuberculosis enrolled in the study will be followed by periodic chart review and data extraction during their treatment and follow-up at participating study sites. For 2.5 years after completing drug treatment, tuberculosis recurrence among study subjects will be identified using periodic chart abstraction and follow-up phone calls every 6 months to determine the 2 year recurrence rate for tuberculosis (TB). M. tuberculosis isolates may be collected from subjects with recurrent TB and analyzed to distinguish between relapse and re-infection.

Study subjects will be asked to provide 10 mL of blood and 5 to 30 mL of sputum for acid-fast bacilli (AFB) smear and culture at entry. Sputum will be cultured for M. tuberculosis and isolates will be tested for drug resistance (DR). The research staff may use molecular DR tests to confirm the agar-growth DR results. In addition, subjects will be asked a series of medical history questions including history of prior tuberculosis, antituberculous treatment, disease contacts, and risk factors associated with tuberculosis; and will be asked to give consent to allow clinical research staff to abstract treatment regimens and results from their inpatient and outpatient medical charts for the duration of their participation in the study (treatment and follow-up).
A 60-year-old man with a history of end-stage renal disease received renal transplant and had decreasing renal function 4 months later. Nuclear medicine renal flow and functional study showed severely decreased blood flow and decreased function of the right renal allograft. There was focal increased radiotracer uptake at blood flow phase around the anastomosis of the renal allograft artery and the right external iliac artery. CT angiogram revealed right external iliac artery pseudoaneurysm. Interventional radiology angiography reconfirmed the pseudoaneurysm and revealed stenosis at the proximal transplant renal artery. After stent placement, however, there was worse renal allograft blood flow.
NEW MATERIAL:A heparin-binding secretory transforming factor (hst-1)-defective mutein. USE:A promoter for therapy of burn and wound and a therapeutic agent for digestive tube ulcer. PREPARATION:For example, RNA is separated from human stomach cancer cells using the guanidine thiocyanate method, etc., and cDNA is synthesized using the separated RNA as a template. The synthesized cDNA is bound to a vector for formation of a cDNA library and the resultant cDNA library is subjected to cloning using a probe consisting of a part of hst-1 base sequence followed by selection of a clone containing DNA capable of coding hst-1. The above-mentioned DNA is separated and the codon of a gene capable of coding an amino acid at the amino terminal of a sequence for defection is changed in order to be bound to a vector. A host is transformed using the resultant recombinant DNA and the obtained transformant is cultured, thus obtaining the objective hst-1-defective mutein.
Thrombotic thrombocytopenic purpura (TTP) is a life-threatening thrombotic disorder associated with a severe deficiency of ADAMTS-13-the protease that cleaves von Willebrand factor. Plasma therapy is the current standard of care for managing acute episodes of TTP, which involves removing patient plasma and replacing it with donor plasma to raise the level of ADAMTS-13 activity. Recently, therapies aimed at replacing ADAMTS-13 have been investigated as possible substitutes or add-ons to plasma therapy for congenital and immune-mediated TTP. Enzyme replacement therapy provides recombinant ADAMTS-13 via intravenous (i.v.) infusion to restore enzyme activity. Recombinant ADAMTS-13-loaded platelets localize to the site of thrombus formation in a more concentrated manner than enzyme replacement or plasma therapy. ADAMTS-13-encoding messenger RNA aims to induce a steady supply of secreted protein and gene therapy is a potentially curative strategy. Overall, targeted ADAMTS-13 replacement therapies may provide better outcomes than plasma therapy by achieving higher levels of ADAMTS-13 activity and a more sustained response with fewer adverse events. Herein, we describe targeted ADAMTS-13 replacement therapies for the treatment of TTP and discuss the advantages and limitations of each approach.
Cachexia is a condition characterized by substantial loss of body weight resulting from the depletion of skeletal muscle and adipose tissue. A considerable fraction of patients with advanced cancer, particularly those who have been diagnosed with pancreatic or gastric cancer, lung cancer, prostate cancer, colon cancer, breast cancer, or leukemias, are impacted by this condition. This syndrome manifests at all stages of cancer and is associated with an unfavorable prognosis. It heightens the susceptibility to surgical complications, chemotherapy toxicity, functional impairments, breathing difficulties, and fatigue. The early detection of patients with cancer cachexia has the potential to enhance both their quality of life and overall survival rates. Regarding this matter, blood biomarkers, although helpful, possess certain limitations and do not exhibit universal application. Additionally, the available treatment options for cachexia are currently limited, and there is a lack of comprehensive understanding of the underlying molecular pathways associated with this condition. Thus, this review aims to provide an overview of molecular mechanisms associated with cachexia and potential therapeutic targets for the development of effective treatments for this devastating condition.
Patients receive fludarabine IV on days -4 to -2. Patients undergo total-body irradiation on day 0. Patients then undergo peripheral blood stem cell transplantation on day 0. Patients receive GVHD prophylaxis comprising tacrolimus PO twice daily on days -3 to 180 and taper and mycophenolate mofetil PO three times daily on days 0-28 and then twice daily until day 180 and taper.
The invention relates to Chinese medicinal powder for treating pharyngitis, which is prepared from the following raw material medicaments by weight: sanchi, safflower, Indian trum etflower seed, rosewood heart wood, myrrh, honeysuckle flower, catechu, great burdock achene, rhubarb, cicada shell, Chinese angelica, cinnabar and frankincense. The Chinese medicinal powder is prepared by the following steps of: preparing the raw material medicaments into powder; sieving the powder with a 200-mesh sieve to prepare the Chinese medicinal powder. The Chinese medicinal powder takes the effects of activating blood and stasis as a principal thing, takes the effects of clearing and disinhibiting throat as supplement, and can address both the symptoms and root cause. The Chinese medicinal powder has the effects of activating blood and dissolving stasis, dispersing swelling and relieving pain, astringing dampness and closing sores, relieving itching and preventing cough, stopping hoarse voice and dumbness, and clearing and disinhibiting throat, and can eliminate diffuse dark red hyperaemia at oropharyngeal parts and promote hyperplastic lymph follicles to recover normal physiological status and physiological functions, and can repair, heal and restore soft tissue injury at the oropharyngeal parts. The Chinese medicinal powder has the advantages of short treatment course, high curative effect, low treatment cost, no adverse reaction and no toxic or side effects. Clinical test treatment for near thousand patients with various pharyngitis diseases proves that the Chinese medicinal powder has an effective rate of over 99 percent, a curative rate of 94.3 percent, obvious medicinal effect, and satisfactory curative effect.
In clinical trials of primarily mild‑to‑moderate heart failure, hypotension and postural hypotension occurred in 9.7% and syncope in 3.4% of subjects receiving COREG compared with 3.6% and 2.5% of placebo subjects, respectively. The risk for these events was highest during the first 30 days of dosing, corresponding to the up‑titration period and was a cause for discontinuation of therapy in 0.7% of subjects receiving COREG, compared with 0.4% of placebo subjects. In a long‑term, placebo‑controlled trial in severe heart failure (COPERNICUS), hypotension and postural hypotension occurred in 15.1% and syncope in 2.9% of heart failure subjects receiving COREG compared with 8.7% and 2.3% of placebo subjects, respectively. These events were a cause for discontinuation of therapy in 1.1% of subjects receiving COREG, compared with 0.8% of placebo subjects.

Postural hypotension occurred in 1.8% and syncope in 0.1% of hypertensive subjects, primarily following the initial dose or at the time of dose increase and was a cause for discontinuation of therapy in 1% of subjects.

In the CAPRICORN trial of survivors of an acute myocardial infarction, hypotension or postural hypotension occurred in 20.2% of subjects receiving COREG compared with 12.6% of placebo subjects. Syncope was reported in 3.9% and 1.9% of subjects, respectively. These events were a cause for discontinuation of therapy in 2.5% of subjects receiving COREG, compared with 0.2% of placebo subjects.

Starting with a low dose, administration with food, and gradual up-titration should decrease the likelihood of syncope or excessive hypotension [see Dosage and Administration (2.1, 2.2, 2.3)]. During initiation of therapy, the patient should be cautioned to avoid situations such as driving or hazardous tasks, where injury could result should syncope occur.
Therapeutic plasmapheresis causes changes in haemostasis by purifying many of the circulating factors involved. Some data are available on changes in circulating haemostasis factors with the Single Plasma Exchange technique and the Double Filtration Plasmapheresis; however, most often these studies are carried out in specific clinical situations where other haemostasis disorders may be present, such as severe renal failure. Furthermore, in these studies, assessment of changes in haemostasis is often limited to coagulation factor assays before and after the session, with little data documenting the kinetics of regeneration of these factors, whose molecular weight and half-life vary widely. To date, there is no clear consensus/recommendation on the management of haemostasis disorders secondary to therapeutic apheresis. The need to correct haemostasis disorders caused by therapeutic apheresis also appears to be consensual in cases of active bleeding.The methods of correcting haemostasis disorders can also be discussed between infusion of coagulation factor and fresh frozen plasma. Finally, apart from these clinical situations, it is not clear when changes in haemostasis associated with coagulation factor deficiency should be corrected. There are no studies available on the kinetics of haemostasis disorders and the risk of haemorrhage following a therapeutic plasmapheresis session, depending on the type of session and the fibrinogen level at the end of the session. The hypothesis of our research is that the existence of a link between fibrinogen level and thrombin generation capacity, post therapeutic plasmapheresis, will enable us to better assess the risk of haemorrhage and to propose preventive measures.
Interferon (IFN) regulatory factors (IRF) are key transcription factors in cellular antiviral responses. IRF7, a virus-inducible IRF, expressed primarily in myeloid cells, is required for transcriptional induction of interferon α and antiviral genes. IRF7 is activated by virus-induced phosphorylation in the cytoplasm, leading to its translocation to the nucleus for transcriptional activity. Here, we revealed a nontranscriptional activity of IRF7 contributing to its antiviral functions. IRF7 interacted with the pro-inflammatory transcription factor NF-κB-p65 and inhibited the induction of inflammatory target genes. Using knockdown, knockout, and overexpression strategies, we demonstrated that IRF7 inhibited NF-κB-dependent inflammatory target genes, induced by virus infection or toll-like receptor stimulation. A mutant IRF7, defective in transcriptional activity, interacted with NF-κB-p65 and suppressed NF-κB-induced gene expression. A single-action IRF7 mutant, active in anti-inflammatory function, but defective in transcriptional activity, efficiently suppressed Sendai virus and murine hepatitis virus replication. We, therefore, uncovered an anti-inflammatory function for IRF7, independent of transcriptional activity, contributing to the antiviral response of IRF7.